Buprenorphine/naloxone, methadone and lofexidine are medications with utility in the treatment of opiate withdrawal. We report the first randomised controlled trial to compare the effects of these two medications on withdrawal symptoms and outcome during opiate induction/stabilisation and detoxification. A double-blind randomised controlled trial was conducted in an outpatient satellite clinic of a specialist drug service. Eighty opiate dependent individuals meeting DSM-IV criteria for opiate dependence, using ⩽ ½ g heroin smoked/chased or ¼ g heroin injected or ⩽ 30mg methadone, with ⩽ 3 years of opioid dependency, underwent a short-term opiate treatment programme involving induction/stabilisation on methadone 30mg or buprenorphine/naloxone 4mg/1mg, followed by detoxification (where the methadone group was assisted by lofexidine). The main outcome measures were urine drug screens for opiates and withdrawal and craving questionnaires. There were no overall differences in positive urine drug screens and drop-outs during any phase of the study. During induction/stabilisation, withdrawal symptoms subsided more slowly for buprenorphine/ naloxone than for methadone, and craving was significantly higher in the buprenorphine/naloxone group (p<0.05, 95% confidence interval -3.5, -0.38). During detoxification, withdrawal symptoms were significantly greater and the peak of withdrawal was earlier for the methadone/lofexidine group than the buprenorphine/naloxone group (p<0.01, 95% confidence interval 3.0, 8.3). Methadone/lofexidine and buprenorphine/naloxone had comparable outcomes during rapid outpatient stabilisation and detoxification in low dose opiate users.
Introduction
Opiate dependence is a major international health problem (11 million heroin users worldwide; Tetrault and Fiellin, 2012) with the majority of opiate dependent individuals relapsing to drug use soon after detoxification from opiates (Spear, 2014) . After assessment, the treatment of opiate dependence involves three phases, namely stabilisation, detoxification and maintenance of abstinence, where effective treatment at each phase is critical to the overall success rates of the whole process. There has long been recognition that during the withdrawal phase, the severity of symptoms experienced can lead to failure to complete the detoxification (Kanof et al., 1993; Rounsaville et al., 1985) , with a reduction in the longer term abstinence rates. The use of pharmacological treatments aimed at reducing the severity of opiate withdrawal is therefore desirable, such as methadone, lofexidine and the different formulations of buprenorphine -Subutex ® (sublingual buprenorphine) and Suboxone ® (sublingual buprenorphine/naloxone).
Our primary purpose in this study was to compare the efficacy of lofexidine/methadone and buprenorphine/naloxone during opiate withdrawal following opiate stabilisation on methadone and buprenorphine/naloxone respectively. Raistrick et al. (2005) have demonstrated non-inferiority of buprenorphine compared with lofexidine in detoxification. Similar studies of detoxification comparing buprenorphine with clonidine have shown benefit of buprenorphine with respect to less severe withdrawal symptoms and craving over 5-6 days (Hussain et al., 2015; Ziaaddini et al., 2010) , an outcome also found with buprenorphine/naloxone over clonidine after 12-13 days' detoxification (Ling et al., 2005; Ziedonis et al., 2009) . Lofexidine, like clonidine, is an alpha-2 adrenergic agonist which is thought to act presynaptically on alpha-2 receptors to block the 'noradrenergic storm' that occurs during opiate withdrawal (Yu et al., 2008) . Lofexidine is preferable to clonidine because it causes less hypotension and sedation (Myles, 1996; NICE, 2007a) , due to less potency at the A subtype of the alpha-2 adrenoreceptors (Herman and O'Brien, 1997) . Lofexidine has become the gold standard in the UK since it was licensed for the treatment of opiate withdrawal in 1992 (Akhurst, 1999) , largely replacing clonidine. As a non-opiate it cannot promote opiate dependence and avoids the regulatory complexities of prescribing controlled drugs. The National Institute for Health and Care Excellence (NICE) guidelines state that lofexidine should be considered for people who have made an informed and clinically appropriate decision to detoxify within a short time period, or not to use methadone or buprenorphine for detoxification, and in those with mild or uncertain dependence including young people (NICE, 2007b) . Alpha-2 adrenergic agonists are interesting in that they demonstrate that the major physical symptoms of opiate withdrawal are due to a downstream effect from the opiate receptors. Lofexidine itself has several side effects such as a dry mouth and mild drowsiness, which can lead to sedation when used with alcohol or other central nervous system depressants.
Buprenorphine is a partial mu opioid receptor agonist and a kappa opioid receptor antagonist (Nutt, 1997) , licensed as an opioid analgesic in the UK in 1978 and for opiate dependence in 1998, and shortly after in many other countries. The clinical use of buprenorphine in the treatment of opioid dependence, both for stabilisation and withdrawal, has been comprehensively reviewed (e.g. Bickel and Amass, 1995; Kahan et al., 2011; Law et al., 2004) . Buprenorphine has a number of advantages over the full mu receptor agonists such as methadone (Lewis, 1985) , and has been extensively studied both in non-dependent opiate users and in users dependent on morphine or methadone. Buprenorphine exhibits a unique profile of effects including a) opioid-agonist activity that promotes treatment compliance (Bickel et al., 1999; Law et al., 1997) ; b) a long duration of action which allows it to be administered daily or on alternate days at high-doses (above 8 mg; Bickel et al., 1999) ; c) a low risk of overdose due to a ceiling on respiratory depressant effect due to its partial agonism (Orman and Keating, 2009 ); d) a slow onset of action with the production of little drug 'high', which means it is less reinforcing and therefore has a lower abuse liability; e) opioid antagonist like activity which occurs both as it can displace full agonists from the mu receptor, and also as a result of the degree of occupation of mu receptors resulting in a partial blocking of the effects of exogenously administered full mu receptor agonists (Bickel et al., 1988a) ; f) cross-tolerance with other mu receptor agonists such that it is similar to methadone in its potential to reduce the use of illicit opiates at doses of < 60-80mg methadone or equivalent; and g) high affinity for the mu opioid receptor which contributes to a low level of withdrawal signs and symptoms (Rance and Dickens, 1978) and limited withdrawal symptoms on abrupt termination, thought to be due to its long duration of action and its slow dissociation from opioid receptors (Lewis, 1995) . This may allow direct transition to naltrexone without the need for an opioid-free period (Law et al., 2004) .
Although buprenorphine is thought to be much safer in overdose than full mu opioid agonists such as methadone, it suffers from a number of problems including the ease with which it can be misused by snorting, or dissolving and injecting, meaning that it also needs to be given by supervised consumption with observation over several minutes. In people with recent heroin use it may precipitate withdrawal symptoms that may be confused with spontaneous withdrawal.
Misuse of buprenorphine led to the development of a combination medication consisting of buprenorphine and naloxone in a 4:1 ratio (Suboxone ® ), which was licensed in the US in 2002 (and in the UK in 2006 and is designed to reduce misuse of buprenorphine if diverted. When taken sublingually the low bioavailability of naloxone means that this drug combination acts clinically like pure buprenorphine. However, if injected intravenously the high bioavailability of naloxone will induce opiate withdrawal symptoms lasting 1-2 h in those taking full mu opioid agonists, and therefore deters further injecting (Law et al., 2004; Yokell et al., 2011) .
In our study, we compared 4mg/1mg buprenorphine/naloxone with 30mg methadone, based on previous results where we transferred patients from 30mg methadone directly onto 4mg buprenorphine 20-24 h after their last methadone dose (Law et al., 1997) , and found no dysphoria or precipitated withdrawal. Buprenorphine given to tolerant individuals caused no detectable agonist effects or drug 'high', but patients reported feeling 'good' effects, and it was 'liked' and well tolerated. We hypothesised that during induction/ stabilisation, there would be no significant differences between the two groups in terms of subjective withdrawal symptoms, opiate cravings, opiate negative urine tests or drop-out from treatment. During detoxification, we hypothesised that the buprenorphine/ naloxone group would have a lower proportion of opiate positive urine tests during detoxification, and would also be associated with lower levels of subjective withdrawal symptoms, opiate cravings and drop-outs from treatment than the methadone/lofexidine group. We further hypothesised that the peak level of withdrawal would be lower and occur later for the buprenorphine/naloxone group than the methadone/lofexidine group.
Methods

Study design and patient recruitment
This study was conducted over an 18 month period (June 1998 -Jan 2000 in Bristol, UK, in an outpatient satellite clinic of a specialist drug service. Eighty opiate-dependent individuals who fulfilled DSM-IV criteria (APA, 1994) were recruited from primary care, hospital and voluntary sector services and were randomised into a double-blind study comparing the efficacy of two short-term opiate treatment programmes consisting of opiate induction/stabilisation followed by detoxification.
The inclusion criteria were that patients had to be aged 16-65 years of either gender with a current primary diagnosis of DSM-IV opiate dependence (APA, 1994), currently selfadministrating prescribed or illicit opiates equivalent to 10-30mg methadone orally (i.e. up to ¼ g illicit heroin intravenously or up to ½ g smoked/chased), and with a history of opioid dependency of ⩽ 3 years in total (excluding periods of abstinence). The exclusion criteria included other drug dependencies sufficient to warrant another DSM-IV diagnosis (apart from caffeine, nicotine and cannabis), high suicide risk and/or warranting hospital admission, clinically significant physical or psychiatric disease, living with others dependent on illicit opiates, taken benzodiazepines in the last five days, being pregnant or lactating, or of child bearing potential and not using a reliable method of contraception.
The purpose of limiting the amount of opiate used prior to entry into the study was to ensure that precipitated withdrawal did not occur during the buprenorphine/naloxone induction, that the stabilisation dose given should be sufficient to cover the opiate use, and that the length of withdrawal with the two regimes would be similar. The purpose of imposing an upper limit on the length of the opiate dependency was to restrict the patient population to those who would not require residential rehabilitation following the detoxification, but whose abstinence could be supported in the community by oral naltrexone and counselling.
All patients were assessed by a medical and psychiatric history, 12-item General Health Questionnaire and Opioid Treatment Inventory, and underwent a physical examination and screening blood tests (urea and electrolytes, liver function tests, full blood count, and plasma viscosity). Patients attended daily (except Sundays and Bank Holidays) for 2-6 weeks of stabilisation, followed by 2.5 weeks of detoxification (see Table 1 for details). The study protocol and procedures were approved by the Bath NHS Research Ethics Committee and all patients gave written informed consent.
The mean age, patterns of drug use, and other demographic characteristics are shown in Table 2 . There were no significant differences between the two groups.
Induction occurred at the full stabilisation dose of 30mg methadone or 4mg/1mg buprenorphine/naloxone, except in four patients who were induced at half the maximum dose because of their low level of opiate use. The first dose of opiate medication was given ⩾ 12 h after the last use of heroin or other short acting opioid (Bickel and Amass, 1995) , and ≥ 20 h after the last dose of methadone (Law et al., 1997) . If patients' last use of opioid had been less than these times, induction was delayed until later in the day, or they were asked to return the following day. All opiate doses were given once daily in the morning by supervised consumption (except on Sundays and Bank holidays, in which case they were dispensed as a take out the previous day). During detoxification in the methadone/lofexidine group the active methadone was terminated on day 3, and active lofexidine was given regularly for 14 days and then as required for a further three days. In the buprenorphine/naloxone group the active buprenorphine was reduced by 1mg every three or four days and terminated on day 10 from a dose of 1mg (Table 3) . Matched placebos were given to maintain blinding. Both the methadone and methadone placebo was obtained from Martindale Pharmaceuticals Ltd (Romford, UK), and were mixed with 50% by volume raspberry syrup (Thornton and Ross Ltd, Huddersfield, UK) immediately prior to dispensing to mask any minor taste difference. Buprenorphine/naloxone and placebo was provided by Reckitt-Benckiser Healthcare (Hull, UK), and lofexidine and placebo by Britannia Pharmaceuticals Ltd (Redhill, UK).
Lofexidine doses were the maximum recommended by the British National Formulary and were given in four equal divided doses daily with only the first dose of the day being supervised. Lofexidine tablets were split where necessary using a tablet splitter (W+W Medsystems, Huddersfield, UK) before dispensing them to the patient, both to provide the correct dose and also when appropriate to give the impression that the daily dose was remaining constant. Patients qualified for progression from the stabilisation to the detoxification phase when they had provided three consecutive urine samples which were clear of illicit opiates (samples taken three times a week, on Monday, Wednesday and Friday). Urine samples were checked for temperature by hand touch immediately after production, and if felt to be suspect were temperature checked (Dinamap TS temperature probe). If below the acceptable temperature, this sample was considered void and a further sample was requested. Any urine sample considered void or missing was treated as a positive sample.
Patients were randomised in blocks of six by Reckitt-Benckiser Healthcare (Hull, UK), who also prepared pre-packaged boxes of medication for each patient number. For use in emergencies the researchers had access to the allocation code for each patient, sealed in individual opaque envelopes, but such use was never required. On entry to the trial, patients were allocated the next treatment number available. During detoxification, but not during stabilisation, patients were allowed adjunctive treatment (see Table 4 ) of a single day's supply (two days' supply on Saturdays) on request of zopiclone 7.5-15 mg (for night sedation), ibuprofen 400mg four times a day (qds) (for aches and pains), promethazine hydrochloride 10-20 mg qds (for anxiety) and hyoscine butylbromide 20 mg qds (for stomach spasms/cramps). Patients were withdrawn from the study if they failed to attend on ≥ 8 consecutive days, if they failed to provide three consecutive opiate-free urine 
Contingency payments
Vouchers from major local food supermarkets (Tesco, ASDA, and Marks & Spencer) totalling £4 per day were issued (given on Mondays, Wednesdays and Fridays during the detoxification phase) to promote provision of opiate negative urines (£2), attendance (£1) and completion of questionnaires (£1), and to encourage retention in the study and the purchase of essential food stuffs. Provision of food stuffs was considered important as about onequarter of patients were mildly anaemic on screening. The use of small monetary payments as reinforcers has been shown to reduce drop-out rates for gradual methadone (McCaul et al., 1984) and buprenorphine (Bickel et al., 1997) detoxification.
Measures
Opiate withdrawal symptoms and cravings Opiate Withdrawal Scale. Subjective withdrawal symptoms were assessed using the 32-item Opiate Withdrawal Scale (OWS; Bradley et al., 1987) , which asks how strong each symptom had been on a four point scale (not at all = 0; mild = 1; moderate = 2; severe = 3) during the last 24 h. Scores range from 0 to 96 with a higher score indicating worse perceived withdrawal symptoms.
Opiate Craving Scale. The strength of craving over the last 24 h was assessed by a six-item scale (Opiate Craving Scale; OCS) that was added to the OWS and scored in the same way by summing the items. The six items were: desires to use opiates (e.g. heroin, methadone); sudden urges to score or use opiates; feeling you couldn't resist opiates (if they were offered); finding yourself making plans to use opiates; desires or urges for other drugs (not opiates). The score ranged from 0 to 18 with higher scores indicating a higher level of craving.
Urine screening
Urine samples were assessed three times a week (on Mondays, Wednesdays and Fridays) using the Biocell Surescreen (Derby, UK) immunological cassettes for opiates only.
Physiological measures
Blood pressure and heart rate were measured daily for the first two weeks of induction/stabilisation and for the first three weeks of withdrawal. These were measured after 5 min in a resting position using a Dinamap Compact TS (Critikon, UK).
Patient perceived treatment effects
These were measured using the Single Dose Opiate Questionnaire (Frazer et al., 1961) , which asked 'How the drug treatment has made you feel over the past 24 hours?' The six items chosen were 'high', 'any drug effect', 'good effect', 'bad effect', 'sick' and 'like'. In addition these items were supplemented with 'normal'. These items were scored using a Visual Analogue Scale, 100mm in length anchored with the labels 'Not at all' and 'Extremely'.
Power calculations and data analysis
We estimated that the difference in opiate positive urine samples during the withdrawal stage would be of the order of 30% (60% in the methadone/lofexidine group and 30% in the buprenorphine/naloxone group). Using this difference in proportions at 80% power, a significance level of 0.05 and using a two-tailed test requires approximately 40 patients in each group. Analysis was conducted using an intention-to-treat paradigm. For time series data a mixed model analysis was adopted using the PROCMIXED module of SAS version 7. Within the mixed model approach covariates included in the model included the baseline value of the outcome variable, severity of dependence at baseline, the outcome of the urine screen for each time point and whether the patient had received adjunct medication. Data was represented as adjusted means and standard errors, the mean difference between the groups and standard errors and the significance value. Treatment drop-outs were analysed using Chi-square.
Results
The flow of patients through the study is illustrated in the CONSORT diagram (Figure 1) . Ninety per cent of patients completed the first two weeks of induction, and 58% completed stabilisation by providing three consecutively opiate clean urines within six weeks of study entry. Of those who completed stabilisation, 96% completed the detoxification phase. 
Induction/stabilisation phase
The main outcomes from the induction/stabilisation phase are reported in Table 5 . No significant differences between the groups were observed for subjective withdrawal symptoms, proportion of negative urine samples, heart rate, diastolic and systolic blood pressure, 'How high', 'Drug effects', 'Good drug effects', 'Bad drug effects', 'How sick' or 'Like' on the Single Dose Opiate Questionnaire. The methadone/lofexidine group had significantly lower scores on the OCS (mean difference -3.5; p = 0.02) and higher scores on the 'Normal' dimension of the Single Dose Opiate Questionnaire (mean difference 10.1; p=0.01) than the buprenorphine/naloxone group. Of the 80 patients randomised 72 successfully completed the induction phase (37 in the methadone/lofexidine group and 35 in the buprenorphine/naloxone group). There were no differences in the numbers successfully completing induction or stabilisation between the groups.
Detoxification phase
The main outcomes from the detoxification phase are reported in Table 6 . There were no significant differences observed between the groups in terms of overall reported craving, proportion of negative urine samples, systolic or diastolic blood pressure. The methadone/lofexidine group had significantly worse levels of subjective withdrawal symptoms (mean difference 2.7; p < 0.01) and higher heart rates (mean difference 7.9; p=0.01) than the buprenorphine/naloxone group. The peak level of withdrawal symptoms occurred at day 8 for the methadone/lofexidine group with a peak value of 29.0. The peak level of withdrawal symptoms for the buprenorphine/naloxone group occurred later at day 12 with a peak value of 23.1 (see Figure 2 ). Use of PRN medications was higher for analgesic and antispasmodic types in the methadone/lofexidine group compared with the buprenorphine/naloxone group, but were similar for the hypnotic and anxiolytic medications (see Table 4 ).
A total of 44 patients successfully completed the detoxification phase (23 in the methadone/lofexidine group and 21 in the buprenorphine/naloxone group). There were no statistical differences between the numbers who completed detoxification between the groups.
Discussion
This is the first randomised controlled trial to directly compare lofexidine after methadone and buprenorphine/naloxone detoxification, in a study using contingency management. Buprenorphine/ naloxone and lofexidine are two medications with different mechanisms of action which have utility in the treatment of opiate withdrawal. In this pragmatic randomised controlled trial, both medications appeared to be well tolerated overall. Both produced the same proportion of opiate negative urine samples during detoxification, both were effective at reducing opiate withdrawal symptoms, and both were associated with surprisingly similar outcomes during induction/stabilisation and detoxification. There were no significant differences in detoxification completion rates (methadone/lofexidine, n=23 (58%); buprenorphine/naloxone, n=21 (53%). Comparisons of buprenorphine/naloxone and methadone as treatments show few significant efficacy differences, apart from improved retention on methadone and reduced opioid positive urine screens during maintenance treatment (CADTH, 2016) . However, we had predicted a significant difference using lofexidine, as noted in trials of clonidine (Hussain et al., 2015; Ling et al., 2005) . It may be that this difference was minimised by the study design, by intensive therapeutic input with a dedicated staff team involving daily contact and crisis intervention, focused weekly counselling and contingency management. The use of contingency management remains rare in the UK setting despite the recommendations from NICE, but may have contributed to the retention and success at stopping on-top use of opioids within six weeks of starting an opiate substitute in both arms of the study. We are unclear as to the extent to which these findings would generalise to clinical settings with less intensive psychosocial support, and it is possible that larger differences between the two treatments would be detected in a clinical rather than a research setting. We are aware that patient preference is at the forefront of clinical healthcare planning in the UK and it is also possible that different outcomes may have been found if patients were able to choose their own treatment. However, our randomised controlled trial design meant that such a choice was not possible. Throughout stabilisation patients on buprenorphine/naloxone reported higher levels of craving, and felt less 'normal' than those on methadone. These findings cannot be explained by precipitated withdrawal symptoms in the buprenorphine/naloxone group, and the most likely explanation is that the agonist doses used were not equivalent, and that a higher dose of buprenorphine/naloxone, such as 6mg/1.5mg or 8mg/2mg, would have been clinically equivalent to 30mg methadone. Indeed, a recent study by Wright et al. (2011) comparing 8mg sublingual buprenorphine with the gradual withdrawal of 30mg methadone (without lofexidine) found comparable abstinence rates after eight days' detoxification. This possible non-equivalence of doses in our study could have potentially confounded the findings during the withdrawal phase of the study, but there is no evidence from the drop-out rates that this occurred. The recent Canadian review of maintenance opioid treatment also commented that patients may have been under-dosed, such that the true effectiveness of the treatment may be greater than the research indicates (CADTH, 2016) . For the same reason, it is also not possible to say with any certainty that stabilisation on buprenorphine/naloxone takes a few days longer than that on methadone as equivalent doses may not have been compared. Precipitated withdrawal would have increased withdrawal (and drop-outs) on induction exclusively in the buprenorphine/naloxone group, but in this study we minimised this effect by inducing patients at 100% of the dose required to cover their withdrawal symptoms (which in almost all cases, apart from four patients, was the full stabilisation dose) and enforcing a time interval of ≥ 12 h for heroin and ≥ 20 h for methadone since the last opioid dose (based on the patient's self-report).
The issue of equivalent doses between buprenorphine and methadone has been long debated (Law et al., 2004) , and as no difference in illicit drug use was detected, it may be that the equivalent dose to ameliorate withdrawal symptoms is different from the dose needed to stop on-top illicit opiate use. This study assumed the dose equivalence of 4mg of buprenorphine was equivalent to 30mg methadone based on our previous work (Law et al., 1997) and the finding that 2mg buprenorphine resulted in more withdrawal than 30mg methadone (Bickel et al., 1988b) . Although previous research studies did appear to find equivalence at the doses of buprenorphine used in this study, these earlier studies used mainly an ethanol based solution of buprenorphine which has a higher bioequivalence than the sublingual tablet (Strain et al., 2004) .
During the induction/stabilisation phase the withdrawal symptoms gradually subsided over two weeks, which was contrary to expectation and clinical experience that withdrawal symptoms typically subside within two to three days. In fact after the two weeks of induction the level of withdrawal symptoms were still 50% above the level they would fall to prior to the detoxification phase, indicating that two weeks failed to provide a sufficient period for the withdrawal symptoms to subside to a low level. This conflict between clinical experience and the withdrawal data is difficult to explain, but one potential explanation is that some patients were using larger amounts of opiates than they reported prior to entry into the study. It is also noteworthy that both the severity of withdrawal symptoms and severity of craving increased temporarily following the take-home dose on Sunday, suggesting that patients did not use the medication as prescribed when it was not supervised. The online Supplementary Material file shows the withdrawal symptoms during induction. It also provides more information about outcomes including data on withdrawal symptoms, craving, drug screen results, VAS scales, blood pressure, pulse and sleep. and in particular graphs directly comparing the level of symptoms during induction and detoxification.
During induction, transient negative effects appeared on days 1 to 3 in the buprenorphine/naloxone group, as indicated by a slight increase in feeling nauseous. As these effects occurred only after the second and subsequent doses of buprenorphine/naloxone, it is unlikely that this is due to precipitated withdrawal (which typically peaks following the first dose of buprenorphine). Nausea most commonly occurs with opiates on induction when the person receives a higher dose that the dose to which the person is tolerant, and may be associated with plasma levels of buprenorphine building up rapidly towards steady state during the first few days.
In terms of the detoxification phase, the shape of the withdrawal curves (Figure 2 ) are very similar except that the methadone/lofexidine group showed a peak on day 8 extending above the buprenorphine/naloxone curve. There was a significant difference in subjective withdrawal between the groups with the buprenorphine/naloxone group reporting a lower level of withdrawal effects, supporting the conclusions of the recent Cochrane review of buprenorphine (Gowing et al., 2009 ). Drop-outs were similar between the groups at the end of the detoxification phase. Delayed withdrawal with fewer subjective effects with buprenorphine compared with lofexidine agrees with the findings of Raistrick et al. (2005) after one week's detoxification.
The cardiovascular effects during withdrawal showed that systolic blood pressure reduced during the first week on lofexidine, but appeared to resolve rapidly and did not elicit clinically relevant symptoms or lead to clinically significant differences overall. Heart rate was significantly elevated during the methadone/lofexidine withdrawal, presumably related to heightened withdrawal symptoms. Other studies have not found such marked cardiovascular effects (Bearn et al., 1996) , which may be because we waited a minimum of 5 min before taking measurements in our patients in order to improve the accuracy of our measurements.
Summary
Both buprenorphine/naloxone and methadone/lofexidine short term are surprisingly similar in terms of termination of illicit drug use, withdrawal symptoms and drop-outs during stabilisation and detoxification with contingency management. In general during stabilisation patients treated with methadone reported fewer negative effects than those treated with buprenorphine/naloxone, and vice versa during detoxification. Results indicate buprenorphine/ naloxone may produce a delayed but more comfortable detoxification compared with lofexidine, and lofexidine may be advantageous for expediting detoxification but with more discomfort than buprenorphine/naloxone.
